Dataset Information

Topp200 - Model of b-Cell Mass, Insulin, and Glucose Kinetics:Pathways to Diabetes

ABSTRACT: A Model of β -Cell Mass, Insulin, and Glucose Kinetics: Pathways to Diabetes BRIANTOPP, KEITHPROMISLOW, GERDADEVRIES, ROBERT MMIURA, DIANE TFINEGOOD Diabetes is a disease of the glucose regulatory system that is associated with increasedmorbidity and early mortality. The primary variables of this system areb-cell mass, plasmainsulin concentrations, and plasma glucose concentrations. Existing mathematical models ofglucose regulation incorporate only glucose and/or insulin dynamics. Here we develop a novelmodel ofb-cell mass, insulin, and glucose dynamics, which consists of a system of threenonlinear ordinary di!erential equations, where glucose and insulin dynamics are fast relativetob-cell mass dynamics. For normal parameter values, the model has two stable"xed points(representing physiological and pathological steady states), separated on a slow manifold bya saddle point. Mild hyperglycemia leads to the growth of theb-cell mass (negative feedback)while extreme hyperglycemia leads to the reduction of theb-cell mass (positive feedback). Themodel predicts that there are three pathways in prolonged hyperglycemia: (1) the physiological"xed point can be shifted to a hyperglycemic level (regulated hyperglycemia), (2) the physio-logical and saddle points can be eliminated (bifurcation), and (3) progressive defects in glucoseand/or insulin dynamics can drive glucose levels up at a rate faster than the adaptation of theb-cell mass which can drive glucose levels down (dynamical hyperglycemi

SUBMITTER: Mohammad Umer Sharif Shohan

PROVIDER: MODEL2001080002 | BioModels | 2020-01-08

REPOSITORIES: BioModels

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	MODEL2001080002?filename=Topp2000.cps	Other
	MODEL2001080002?filename=Topp2000.xml	Xml

Items per page:

1 - 2 of 2

Publications

A model of beta-cell mass, insulin, and glucose kinetics: pathways to diabetes.

Topp B B Promislow K K deVries G G Miura R M RM Finegood D T DT

Journal of theoretical biology 20001001 4

Diabetes is a disease of the glucose regulatory system that is associated with increased morbidity and early mortality. The primary variables of this system are beta-cell mass, plasma insulin concentrations, and plasma glucose concentrations. Existing mathematical models of glucose regulation incorporate only glucose and/or insulin dynamics. Here we develop a novel model of beta -cell mass, insulin, and glucose dynamics, which consists of a system of three nonlinear ordinary differential equatio ...[more]

PMID: 11013117

Similar Datasets

Project description:Relative beta cell deficit and increased beta cell apoptosis are hallmarks of type 2 diabetes (T2D). The Insulin/Insulin Growth Factor (Igf) signaling pathway is an established regulator of beta cell survival and is found downregulated in human T2D islets. The Insulin Receptor Substrate 2 (Irs2) plays a central role in the coordination of this pathway in beta cells. Thus, Irs2 knockout mice (Irs2 -/-) exhibit increased beta cell apoptosis that leads to a progressive decline of beta cell mass and hyperglycaemia. In this study, we sought to determine whether the anti-diabetic compound sodium tungstate could prevent the onset of diabetes in Irs2 -/- mice. Oral administration of tungstate resulted in an overall improvement in whole-body glucose tolerance in Irs2 -/- mice which correlated with increased beta cell mass. Enhanced beta cell mass was due to a dramatic reduction of beta cell apoptosis without changes in proliferation. Whole genome gene profiling analysis of islets isolated from treated Irs2 -/- mice confirmed a broad impact of tungstate on cell death pathways. Mechanistically, tungstate induced Erk1/2 phosphorylation in islets in vitro and, in agreement, treated Irs2 -/- islets exhibited increased basal Erk1/2 phosphorylation. Tungstate also downregulated expression of apoptosis-related genes in Irs2-/- islets in vitro, uncovering a direct effect of this compound in islets. All together, our data demonstrate that tungstate can restore beta cell mass and glucose homeostasis in a context of deficient Insulin/Igf signaling. This study underscores the importance of developing strategies specifically designed to arrest beta cell apoptosis as a means to prevent progressive beta cell failure in diabetes. 10-week old WT and Irs2 -/- mice were randomly divided into two treatment group, in a total of 4 experimental groups. For 21 days one group received distilled water as drinking water (untreated group) whilst the other received ad libitum a solution of 2mg/ml of sodium tungstate in distilled water (treated group). For each experimental group 2 independent samples were analysed, in a total of 8 samples.